Display options
Cite
Doss RW, El-Rifaie AA, Gohary YM, et al. Vitamin D Receptor Expression in Vitiligo. Indian J Dermatol. 2015;60(6):544-8doi: 10.4103/0019-5154.169123.
Doss, R. W., El-Rifaie, A. A., Gohary, Y. M., & Rashed, L. A. (2015). Vitamin D Receptor Expression in Vitiligo. Indian journal of dermatology, 60(6), 544-8. https://doi.org/10.4103/0019-5154.169123
Doss, Reham William, et al. "Vitamin D Receptor Expression in Vitiligo." Indian journal of dermatology vol. 60,6 (2015): 544-8. doi: https://doi.org/10.4103/0019-5154.169123
Doss RW, El-Rifaie AA, Gohary YM, Rashed LA. Vitamin D Receptor Expression in Vitiligo. Indian J Dermatol. 2015 Nov-Dec;60(6):544-8. doi: 10.4103/0019-5154.169123. PMID: 26677265; PMCID: PMC4681190.
Copy Download .nbib Format: NLM
Share it on

Indian J Dermatol. 2015 Nov-Dec;60(6):544-8. doi: 10.4103/0019-5154.169123.

Vitamin D Receptor Expression in Vitiligo.

Indian journal of dermatology

Reham William Doss, Abdel-Aziz El-Rifaie, Yasser M Gohary, Laila A Rashed

Affiliations

  1. Department of Dermatology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
  2. Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt.

PMID: 26677265 PMCID: PMC4681190 DOI: 10.4103/0019-5154.169123

Abstract

BACKGROUND: Vitiligo is a progressive depigmenting disorder characterized by loss of functional melanocytes from the epidermis. The etiopathogenesis of vitiligo is still unclear. Vitamin D has stimulatory effects on melanocytes and acts through its nuclear Vitamin D receptor (VDR) on target cells.

AIMS AND OBJECTIVES: The purpose of this study was to declare the role of Vitamin D in the pathogenesis of vitiligo.

MATERIALS AND METHODS: This case-control study included 30 vitiligo patients and 30 age, gender-matched healthy controls. Blood samples were withdrawn from the study subjects, and the serum 25(OH) D level was determined by an enzyme-linked immunosorbent assay technique. Serum 25(OH) D levels were divided into: Normal or sufficient (≥30 ng/ml), insufficient (< 30-> 20ng/ml), and deficient (≤20 ng/ml) levels. Skin biopsies were obtained from the depigmented lesions and clinically normal skin of vitiligo patients and from the controls, and VDR gene expression was determined using real-time polymerase chain reaction.

RESULTS: Only 10 patients with vitiligo (33.3%) had sufficient serum 25(OH) D levels (≥30 ng/ml), 12 patients (40%) had insufficient levels, and 8 patients (26.7%) had deficient levels. On the other hand, most of the controls (96.7%) had sufficient levels. The mean serum 25(OH) D level in patients was significantly decreased compared to controls (P < 0.001). The VDR-mRNA expression was also significantly decreased in lesional and nonlesional skin of patients compared to controls (P < 0.001, P < 0.001, respectively).

CONCLUSION: Vitamin D deficiency influences the extent of vitiligo and could contribute to the pathogenesis of vitiligo through its immunomodulatory role and its role in melanogenesis.

Keywords: 25-hydroxy Vitamin D; Vitamin D receptor; Vitiligo; enzyme-linked immunosorbent assay; real-time polymerase chain reaction

References

  1. Clin Chem. 2009 Aug;55(8):1584-5 - PubMed
  2. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S - PubMed
  3. J Am Acad Dermatol. 2010 Jun;62(6):937-41 - PubMed
  4. Dermatology. 2012;224(4):361-8 - PubMed
  5. J Dermatol. 2003 Jun;30(6):429-37 - PubMed
  6. J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S205-8 - PubMed
  7. Methods. 2001 Dec;25(4):402-8 - PubMed
  8. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):614-9 - PubMed
  9. Mol Endocrinol. 2005 Nov;19(11):2685-95 - PubMed
  10. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):749-57 - PubMed
  11. Curr Drug Targets. 2008 Apr;9(4):345-59 - PubMed
  12. Eur J Dermatol. 2013 May-Jun;23(3):350-5 - PubMed
  13. Br J Dermatol. 2012 Sep;167(3):688-91 - PubMed
  14. Arch Dermatol. 1997 Jul;133(7):922-3. - PubMed
  15. Photodermatol Photoimmunol Photomed. 2013 Feb;29(1):34-40 - PubMed
  16. J Cell Physiol. 1988 Aug;136(2):273-80 - PubMed
  17. Arch Dermatol. 1999 Apr;135(4):407-13 - PubMed
  18. PLoS One. 2012;7(12):e52778 - PubMed
  19. Clin Endocrinol (Oxf). 2012 Mar;76(3):315-25 - PubMed
  20. J Invest Dermatol. 2002 Sep;119(3):583-9 - PubMed
  21. Nat Rev Immunol. 2008 Sep;8(9):685-98 - PubMed
  22. J Invest Dermatol. 1988 Jun;90(6):882-4 - PubMed

Publication Types